EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 11 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations Aiming to Prevent New Cancer Cases, ESMO Calls for Increased Minimum EU Excise Duty Rates on Tobacco Products in its Response to the Public... MOST POPULAR Maximizing the Prospects for Progress Against Cancer June 11, 2018 Medicare Advantage Plans: Read the Fine Print November 16, 2020 Bride’s Escorted Down Aisle By Dad Of Organ Donor Who Saved... October 11, 2021 EMA Recommends Granting a Marketing Authorisation for Pomalidomide Viatris January 17, 2024 Load more HOT NEWS Breathing Amidst Uncertainty FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality... A cut above: Making drug discovery more efficient using CRISPR
